KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables Refunds (2023 - 2025)

Sarepta Therapeutics has reported Receivables Refunds over the past 3 years, most recently at $14.3 million for Q3 2025.

  • For Q3 2025, Receivables Refunds rose 25.2% year-over-year to $14.3 million; the TTM value through Sep 2025 reached $14.3 million, up 25.2%, while the annual FY2024 figure was $13.1 million, 91.37% up from the prior year.
  • Receivables Refunds for Q3 2025 was $14.3 million at Sarepta Therapeutics, up from $7.2 million in the prior quarter.
  • Over five years, Receivables Refunds peaked at $14.3 million in Q3 2025 and troughed at $6.9 million in Q4 2023.
  • A 3-year average of $9.8 million and a median of $8.4 million in 2024 define the central range for Receivables Refunds.
  • Biggest five-year swings in Receivables Refunds: surged 91.37% in 2024 and later fell 13.92% in 2025.
  • Year by year, Receivables Refunds stood at $6.9 million in 2023, then soared by 91.37% to $13.1 million in 2024, then increased by 8.89% to $14.3 million in 2025.
  • Business Quant data shows Receivables Refunds for SRPT at $14.3 million in Q3 2025, $7.2 million in Q2 2025, and $7.0 million in Q1 2025.